Hologic (Hologic) Ending Cash Position : $1,932 Mil (As of Dec. 2023)

View and export this data going back to 1990. Start your Free Trial

What is Hologic Ending Cash Position?

Hologic's Ending Cash Position for the quarter that ended in Dec. 2023 was $1,932 Mil.

Hologic's quarterly Ending Cash Position declined from Jun. 2023 ($2,765 Mil) to Sep. 2023 ($2,756 Mil) and declined from Sep. 2023 ($2,756 Mil) to Dec. 2023 ($1,932 Mil).

Hologic's annual Ending Cash Position increased from Sep. 2021 ($1,170 Mil) to Sep. 2022 ($2,340 Mil) and increased from Sep. 2022 ($2,340 Mil) to Sep. 2023 ($2,756 Mil).

Hologic Ending Cash Position Historical Data

The historical data trend for Hologic's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Hologic Ending Cash Position Chart

Hologic Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Ending Cash Position

Get a 7-Day Free Trial

601.80

701.00

1,170.30

2,339.50

2,755.70

Hologic Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Ending Cash Position	Get a 7-Day Free Trial															2,441.30	2,582.20	2,765.00	2,755.70	1,932.10

Hologic Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Hologic's Ending Cash Position for the fiscal year that ended in Sep. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2339.5	+	416.2
	=	2,756

Hologic's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position	=	Beginning Cash Position	+	Net Change in Cash
	=	2755.7	+	-823.6
	=	1,932

Hologic Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Hologic's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Hologic (Hologic) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Hologic Inc (NAS:HOLX) » Definitions » Ending Cash Position

Comparable Companies

Traded in Other Exchanges

HOLX:Mexico HO1:Germany HOLX:Austria

Address

250 Campus Drive, Marlborough, MA, USA, 01752

Website

http://www.hologic.com

Hologic manufactures proprietary products for the healthcare needs of women. The company operates in five segments: diagnostics (60% of total sales, boosted by pandemic), breast health (14% of sales, suppressed by pandemic), surgical (11%), and skeletal health (1%). While the company traditionally focused on breast health, the acquisition of Gen-Probe put greater emphasis on commercial diagnostics. The United States accounts for the largest portion of the firm's revenue (69%), followed by Europe (20%), Asia (8%), and other international markets (3%). Hologic is headquartered in Bedford, Massachusetts.

Executives

Charles J Dockendorff	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Scott T Garrett	director	35 CROSBY DRIVE, BEDFORD MA 01730
Stephen P Macmillan	director, officer: President and CEO	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Essex D Mitchell	officer: Div. President, GYN Surgical	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Nanaz Mohtashami	director	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Jennifer M Schneiders	officer: President, Diag. Solutions	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Benjamin Jordan Cohn	officer: Principal Accounting Officer	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Stacey D. Stewart	director	5920 WALHONDING ROAD, BETHESDA MD 20816
Elisabeth A Hellmann	officer: SVP, Human Resources	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Kevin R Thornal	officer: Div. President, Diagnostics	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
John M. Griffin	officer: General Counsel	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Karleen Marie Oberton	officer: Corp. VP, Finance & Acconting	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Erik S Anderson	officer: Div. Pres., Breast & Skeletal	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Jan Verstreken	officer: Group President, International	250 CAMPUS DRIVE, MARLBOROUGH MA 01752
Allison P Bebo	officer: SVP, Human Resources	250 CAMPUS DRIVE, MARLBOROUGH MA 01752